UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 7, 2019

Date of Report (date of earliest event reported)

OpGen, Inc. (Exact name of Registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization) 001-37367 (Commission File Number) 06-1614015 (I.R.S. Employer Identification Number)

708 Quince Orchard Road, Suite 205 Gaithersburg, MD 20878 (Address of principal executive offices)

(240) 813-1260 (Registrant's telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[_]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[_]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[_]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	OPGN	The Nasdaq Capital Market
Common Stock Warrants (IPO)	OPGNW	The Nasdaq Capital Market

Item 2.02 Results of Operations and Financial Condition.

On August 7, 2019, OpGen, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2019. The full text of such press release is furnished as Exhibit 99.1 to this report.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press Release, dated August 7, 2019, issued by OpGen, Inc.

The information included herein and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 7, 2019 OpGen, Inc.

By: /s/ Timothy C. Dec

Name: Timothy C. Dec

Title: Chief Financial Officer



OpGen Reports Second Quarter 2019 Financial Results and Provides Business Update

Revenue up 28% Quarter-over-Quarter

Progression of 510(k) submission to the FDA for clearance of the Acuitas® AMR Gene Panel test for bacterial isolates

Conference call to be held at 4:30 p.m. Eastern Time today

GAITHERSBURG, Md., August 7, 2019 -- OpGen, Inc. (NASDAQ: OPGN) today reported financial and operating results for the three and six months ended June 30, 2019 and provided a business update. Total revenue for the second quarter of 2019 was \$1.0 million, compared with \$0.8 million for the second quarter of 2018. Recent business highlights include:

- Submission and ongoing review of 510(k) pre-market notification to the U.S. Food and Drug Administration ("FDA") for clearance of the Acuitas[®] AMR Gene Panel test for the detection of antimicrobial resistance genes in bacterial isolates;
- Initiation of testing to support *de novo* submission for our lead rapid molecular diagnostic test, the Acuitas AMR Gene Panel Urine:
- Achievement of second \$500,000 program milestone under the New York State Infectious Disease Digital Health Initiative demonstration project;
- Presentation of new data demonstrating the potential clinical utility of Acuitas AMR Gene Panel and Acuitas Lighthouse[®] for antibiotic-resistant urinary tract infection patient management and for rapid carbapenem-resistant bacteria outbreak detection during a podium presentation at ASM Microbe 2019;
- Presentation of data by collaborator, Geisinger, obtained from the first multisite assessment evaluating the potential clinical utility of OpGen's Acuitas AMR Gene Panel using clinical samples presented at ASM Microbe 2019:
- Advancement of South America initiative to commercialize rapid testing products, marked by the closing of OpGen's first customer accounts in Colombia; and
- Launch of new OpGen website and branding to reflect our transformation into an innovative commercial organization and leader in precision medicine.

"During the second quarter, we continued to execute against OpGen's highest priority of bringing our novel Acuitas AMR Gene Panel and Acuitas Lighthouse Software to market. We engaged in ongoing dialogue with the FDA regarding our recent 510(k) submission for the Acuitas AMR Gene Panel for use with bacterial isolates. We are encouraged by our interactions with the Agency and we are continuing to work towards receiving our first FDA clearance during 2019," said Evan Jones, Chairman and CEO of OpGen.

"We are also working to complete two (2) additional FDA pre-market submissions for our lead rapid molecular diagnostic test, the Acuitas AMR Gene Panel Urine, and for the Acuitas Lighthouse Software. We have begun testing to support the AMR Gene Panel Urine submission, and we plan to complete the trials and make an initial FDA submission by year-end or in the first quarter of 2020."

"Finally, we continued to build commercial momentum in preparation of our anticipated receipt of regulatory clearance. To meet our capital needs, which will enable us to pursue the development and regulatory work to complete our additional FDA filings and, once clearance is received, execute a successful commercial launch, we are considering multiple alternatives ranging from strategic financings to other potential transactions. This consideration includes potential partnering arrangements and business combination transactions in order to obtain sufficient financing so we can continue to deliver distinct and differentiated precision medicine capabilities and maximize our shareholder value." Evan Jones concluded.

2019 Second Quarter and First Half Financial Results

- Total revenue for the second quarter of 2019 was \$1.0 million, compared with \$0.8 million for the second quarter of 2018. Total revenue for the first half of 2019 was \$2.0 million, compared with \$1.6 million for the first half of 2018;
- Operating expenses for the second quarter 2019 were \$3.6 million, compared with \$4.0 million for the second quarter of 2018. Operating expenses for the first half of 2019 were \$8.4 million, compared with \$7.9 million for the first half of 2018;
- The net loss for the second quarter of 2019 was \$2.6 million or \$0.15 per share, compared with a net loss of \$3.3 million or \$0.57 per share for the second quarter of 2018. The net loss for the first half of 2019 was \$6.4 million or \$0.48 per share, compared with a net loss of \$6.4 million or \$1.29 per share for the first half of 2018; and
- Cash and cash equivalents were \$3.1 million as of June 30, 2019.

Business and Operations Outlook

- Obtain FDA clearance to market the Acuitas AMR Gene Panel for use with bacterial isolates;
- Complete clinical studies and file de novo submissions with the FDA for the Acuitas AMR Gene Panel Urine and the Acuitas Lighthouse Software for rapid testing of urine specimens and prediction of antibiotic resistance to front-line antibiotics;
- Continue to install Acuitas AMR Gene Panel systems in support of Research Use Only ("RUO") sales and full launch following first FDA clearance;
- Expand commercial activities to support FDA clearance and launch of the Acuitas AMR Gene Panel products;
- Enter data collection phase for New York State Infectious Disease Digital Health Initiative demonstration project; and
- · Commercialize rapid testing products in South America, using Colombia as a springboard.

Annual Meeting

We are holding our Annual Meeting of stockholders on August 22, 2019 and are asking our stockholders to approve a reverse stock split proposal to help us maintain our Nasdaq Capital Market listing and position the Company to pursue potential partnering arrangements and business combination transactions.

Conference Call Information

OpGen management will hold a conference call today, August 7, 2019 at 4:30 p.m. ET to discuss second quarter 2019 financial results and other business activities, and answer questions.

Dial-in Information

U.S. Dial-In Number: (844) 420-8185

International Dial-In Number: (216) 562-0481 Conference ID: 7288909 Webcast URL: https://edge.media-server.com/mmc/p/6grvivzp

Replay Dial-in Information

U.S. Dial-In Number: (855)-859-2056

International Dial-In Number: (404)-537-3406 Conference ID: 7288909

A live webcast of the conference call can be accessed by visiting the Investor Relations section of the company's website at **www.ir.opgen.com**. A replay of the webcast will be available shortly after the conclusion of the call for 90 days.

About OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

Our molecular diagnostics and informatics products, product candidates and services combine our Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with our proprietary, curated MDRO knowledgebase. We are working to deliver our products and services, some in development, to a global network of customers and partners. The Acuitas AMR Gene Panel (RUO) is intended for Research Use Only and is not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures. For more information, please visit www.opgen.com.

OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.

Forward-Looking Statements

This press release includes statements relating to OpGen's outlook for 2019 and 2020. These statements and other statements regarding OpGen's future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to timely and cost-effectively seek and obtain regulatory clearance for and commercialize our product and services offerings, our ability to successfully complete the demonstration project portion of the New York State Infectious Disease Digital Health Initiative, the rate of adoption of our products and services by hospitals and other healthcare providers, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2018, and subsequent filings. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen Contact:

Michael Farmer Vice President, Marketing (240) 813-1284 mfarmer@opgen.com InvestorRelations@opgen.com

Press Contact:

Matthew Bretzius
FischTank Marketing and PR matt@fischtankpr.com

Investor Contacts:

Joe Green Edison Group jgreen@edisongroup.com

OpGen, Inc. Condensed Consolidated Balance Sheets (unaudited)

Assets Current assets Cash and cash equivalents \$ 3,055,80* \$ 4,72,487 Accounts receivable, net 772,914 373,858 Inventory, net 567,422 543,747 Prepad expenses and other current assets 4,574,586 578,301 Property and equipment, net 197,502 1,221,827 Pinance leaser right-of-use assets, net 99,472 - Operating lease right-of-use assets 3,381,830 - Ordovill 600,814 600,814 Intaggible assets, net 951,458 1,985,366 Other noncurrent assets 241,182 259,346 Other noncurrent assets 241,182 259,346 Other noncurrent assets 8,305,361 1,985,366 Total assets 8,21,28,983 1,623,751 Lower Hibblities 8,25,893 1,623,751 Accouncy payable 1,25,893 1,623,751 Accounty payable 9,93 1,524,893 Accrued liabilities 9,93 1,524,903 Bort-term operating lease liabilities 9,93			June 30, 2019	December 31, 2018		
Cash and cash equivalents \$ 3,05,894 \$ 4,572,487 Accounts receivable, net 775,214 373,858 Inventory, net 567,422 543,747 Prepai expenses and other current assets 4,574,868 578,301 Propert and equipment, net 984,742 Pinance lease right-of-use assets, net 984,742 Operating lease right-of-use assets 1381,830 Good will 591,458 1,083,60 Other noncurrent assets 241,822 29,346 Very and the first and stockholders' Equit 25,252,828 30,503,603 Total assets and Stockholders' Equit 21,252,908 1,623,751 Accounts payable 21,252,908 1,623,751 Accurred labilities 35,352,122 4,343,97						
Accounts receivable, net 772,914 373,888 Inventory, net 567,422 543,747 Prepaid expenses and other current assets 178,356 292,918 Total current assets 187,506 578,000 Property and equipment, net 197,602 122,1827 Finne clease right-of-use assets, net 984,742 —— Operating lease right-of-use assets 600,814 600,814 Interport assets 291,485 1,883,00 Ober of the contract assets 291,485 1,883,00 Other noncurrent assets 291,485 1,883,00 Other noncurrent assets 291,485 1,883,00 Other noncurrent assets 291,485 1,883,00 Total uses 291,485 1,883,00 Total uses 291,485 1,883,00 Total uses 291,485 1,883,00 Total uses 1,282,00 1,983,00 Accrued compassion and benefits 1,983,00 1,983,10 Accrued clinibilities 39,93 1,582,40 Bort-removen 31,30						
Invention, net 567,42 543,74 Prepaid expense and other current assets 178,356 292,918 Total current assets 187,500 788,010 Properly and equipment, net 198,742 2—2 Finance lease right-of-use assets, net 98,742 2—2 Operating lease right-of-use assets 381,830 ————————————————————————————————————		\$		\$		
Break of External sasts 178,356 292,318 Total current assets 4,74,368 78,300 Property and equipment et 199,02 122,1827 Finance lease right-of-use assets, net 98,474						
Interest assets 4,574,586 5,783,010 Proper yan dequipment net 197,502 1,21,287 Finance lease right-of-use assets, net 984,742 — Operating lease right-of-use assets 1,381,830 — Goodwill 600,814 600,814 Intangible assets, net 951,458 1,085,366 Other noncurrent assets 241,182 259,346 Other noncurrent assets 8,932,114 8,085,366 Total asset 8,932,114 8,085,366 Intal stockholders' Equity 8,085,366 8,085,366 Total asset 8,085,361 8,085,366 Accrued labilities 1,190,500 1,041,573 Accrued compensation and benefits 1,190,500 1,041,573 Accrued labilities 320,667 902,019 Deferred revenue 9,993 15,824 Short-term finance lease liabilities 358,352 39,345 Short-term funance lease liabilities 5,188,12 438,100 Deferred revenue 5,189,12 434,100 More payable <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>						
Property and equipment, net 197,502 1221,827 Finance lease right-of-use assets net 984,742 ————————————————————————————————————	•					
Finance lease right-of-use assets, net 984,742 — Operating lease right-of-use assets 1,381,830 — Goodwill 600,814 600,814 Intagible assets, net 951,458 1,085,366 Other noncurrent assets 241,182 25,936 Total asset 8,032,114 8,050,363 Liabilities and Stockholders' Equity 8 1,258,908 1,623,751 Accounts payable 1,190,500 1,041,573 Accrued dompensation and benefits 1,190,500 1,041,573 Accrued thillities 820,667 90,019 Accrued presente 9,93 15,824 Short-term notes payable 343,330 380,955 Short-term finance lease liabilities 56,632 399,345 Short-term operating lease liabilities 5,58,712 4,381,07 Deferred revenue 49,893 60,340 Marrant liabilities 379,825 431,182 Very apable 379,825 437,182 Marrant liabilities 379,825 437,182 Long-term finance l	Total current assets					
Operating lease right-of-use assets 1,381,830 — Goodwill 600,814 600,814 Intangible assets, net 951,458 1,085,366 Other noncurrent assets 241,182 259,346 Total asset 8,032,114 8,050,301 Labilities and Stockholders' Equity 8 1,257,000 Current liabilities 1,190,500 1,041,573 Accured compensation and benefits 1,190,500 1,041,573 Accured compensation and benefits 820,667 902,019 Accured compensation and benefits 9,933 1,582,100 Accured compensation and benefits 9,933 1,582,100 Morent evenue 9,933 1,582,100 Deferred revenue 9,933 1,582,100 Short-term finance lease liabilities 368,892 —— Fotal current liabilities 5,158,712 4,381,000 Deferred rent 9,489 660,430 Varrant liabilitie 1,071,677 — Long-term finance lease liabilities 379,852 437,880 Long-term finance	Property and equipment, net		197,502		1,221,827	
Goodwill 600,814 600,814 Intangible assets, net 951,458 1,085,366 Other noncurrent assets 241,162 259,346 Total assets 8,032,114 8,050,363 Lishilities and Stockholders' Equity 8 8,032,101 Current lishilities 8 1,258,908 1,623,751 Accrued compensation and benefits 1,109,500 1,041,573 Accrued lishilities 820,667 90,201 Deferred revenue 9,993 1,582,402 Short-term protein passe lishilities 376,322 399,345 Short-term protein glease lishilities 576,322 399,345 Short-term protein glease lishilities 5,188,712 4,381,007 Poffered ret 9,789,22 49,481 60,342 Note payable 9,188,712 4,381,007 60,342 399,345 60,342 60,342 80,343,107 60,342 80,343,107 60,342 80,343,107 60,342 80,343,107 60,342 80,343,107 60,343 80,343 80,343,107 60,343 80,343,10					_	
Intangible assets, net 951,458 1,085,366 Other noncurrent assets 241,182 259,346 Total asset 8,932,114 259,368 Libilities and Stockholders' Equity 8,932,114 8,950,363 Current liabilities 1,258,908 \$ 1,623,751 Accounts payable \$ 1,905,00 1,014,733 Accrued compensation and benefits 1,905,00 1,023,751 Accrued liabilities 9,903 1,528,90 Deferred revene 9,903 1,528,90 Short-term inneate clase liabilities 343,33 39,855 Short-term operating lease liabilities 958,992 — Fold current liabilities 5,158,712 4,381,00 Note payable 49,895 660,340 Warrant liability 49,895 67 Long-term operating lease liabilities 379,825 437,10 Long-term operating lease liabilities 379,825 437,10 Long-term operating lease liabilities 3,002,10 4,002,00 Long-term operating lease liabilities 1,071,67 — <tr< td=""><td></td><td></td><td>1,381,830</td><td></td><td>_</td></tr<>			1,381,830		_	
Other noncurrent assets 241,182 259,346 Total assets 8,893,2114 8,895,036 Lisbilities and Stockholders' Equity Seconds 1,993,211 8,895,036 Current Lisbilities Seconds 1,993 1,623,751 Accrued compensation and benefits 1,190,500 1,041,573 Accrued Lisbilities 820,667 90,201 Deferred revenue 9,993 15,824 Short-term notes payable 343,330 398,595 Short-term operating lease liabilities 576,322 399,345 Short-term operating lease liabilities 5,185,712 4,381,070 Deferred revt 1,587,122 3,31,070 Deferred rent 494,897 660,340 Warrant liabilities 379,825 437,189 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 —— Total current liabilities 379,825 437,189 Long-term finance lease liabilities 1,071,677 —— Total current liabilities 1,071,677	Goodwill				600,814	
Total assets \$ 8,932,114 \$ 8,950,363 Liabilities and Stockholders' Equity Urrent liabilities Cecurent liabilities \$ 1,258,908 \$ 1,623,751 Accound compensation and benefits 1,190,500 1,041,573 Accrued cimpensation and benefits \$ 20,667 902,019 Accrued liabilities \$ 20,667 902,019 Deferred revenue 9,993 15,824 Short-term notes payable 343,330 398,595 Short-term poreating lease liabilities 576,322 399,345 Short-term finance lease liabilities 5,188,712 4,381,107 Deferred rent 9,599,92 Total current liabilities 9,589,92 Note payable 494,897 660,340 Warrant liability 9 1,02,919 Marrant liabilities 379,825 437,189 Long-term inance lease liabilities 379,825 437,189 Long-term poerating lease liabilities 1,011,677 Combinets 1,011,677 Total liability	Intangible assets, net		951,458		1,085,366	
Patient Pati	Other noncurrent assets		241,182		259,346	
Current liabilities \$ 1,258,908 1,623,751 Accurud compensation and benefits 1,190,500 1,041,573 Accurud liabilities 820,667 902,019 Deferred revenue 9,993 15,884 Short-term notes payable 343,330 398,955 Short-term operating lease liabilities 576,322 99,934 Short-term operating lease liabilities 558,992 — Total current liability 5,158,712 4,381,007 Deferred rent — 60,340 Warrant liability — 60 Varyable 494,897 600,340 Warrant liabilities 379,825 437,810 Long-term operating lease liabilities 379,825 437,810 Long-term operating lease liabilities 1,071,671 — Commitments — 6,645,720 Stockholders' equit 176,457 86,457 Common stock, \$0.01 par value; 50,000,000 shares authorized; 76,457,20 and 8,645,720 shares issued and outstanding at June 30, 2019 and 50,000,000 shares authorized; none issued and outstanding at June 30, 2019 and 50,000,000 shares authorized; none issued and outstanding at June 30	Total assets	\$	8,932,114	\$	8,950,363	
Accounts payable \$ 1,258,908 \$ 1,623,751 Accrued compensation and benefits 1,190,500 1,041,573 Accrued liabilities 820,667 902,019 Deferred revenue 9,993 15,824 Short-term notes payable 343,330 398,595 Short-term operating lease liabilities 576,322 39,345 Short-term operating lease liabilities 958,992 — Total current liabilities 5,158,712 4,381,107 Deferred rent — 162,919 Note payable 49,4897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 379,825 437,189 Long-term finance lease liabilities 7,105,111 5,641,622 Commitments 7 7,105,111 5,641,622 Commitments 7 7,105,111 5,641,622 Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 8	Liabilities and Stockholders' Equity					
Accrued compensation and benefits 1,190,500 1,041,573 Accrued liabilities 820,667 902,019 Deferred revenue 9,993 15,824 Short-term notes payable 343,330 398,595 Short-term operating lease liabilities 576,322 399,345 Short-term operating lease liabilities 51,58,712 4,381,107 Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 1,071,677 — Total liabilities 1,071,677 — Commitments 5,641,622 437,189 Stockholders' equity — 6 Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Preferred stock, \$0.01 par value; 10,0	Current liabilities					
Accrued liabilities 820,667 902,019 Deferred revenue 9,993 15,824 Short-term notes payable 343,330 398,595 Short-term finance lease liabilities 576,322 399,345 Short-term operating lease liabilities 958,992 — Total current liabilities 5,158,712 4,381,107 Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 7,015,111 — Competerm operating lease liabilities 7,015,111 5,641,622 Competerm operating lease liabilities 7,015,111 5,641,622 Commitments Stockholders' equity Total liabilities 7,015,111 — Commitments Stockholders' equity 176,457 86,457 Stockholders' equity 176,457 86,457 Preferred stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 176,457 86,457	Accounts payable	\$	1,258,908	\$	1,623,751	
Deferred revenue 9,993 15,824 Short-term notes payable 343,330 398,595 Short-term finance lease liabilities 576,322 399,345 Short-term operating lease liabilities 958,992 — Total current liabilities 5,158,712 4,381,107 Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Tous term operating lease liabilities 1,071,677 — Commitments Stockholders' equity — Stockholders' equity — 6,641,622 Common stock, \$0,01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and 86,457 December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0,01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively <	Accrued compensation and benefits		1,190,500		1,041,573	
Short-term notes payable 343,330 398,595 Short-term finance lease liabilities 576,322 399,345 Short-term operating lease liabilities 958,992 — Total current liabilities 5,158,712 4,381,107 Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity — 6 Stockholders' equity — 5,641,622 Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018 are particularly and parti	Accrued liabilities		820,667		902,019	
Short-term finance lease liabilities 576,322 399,345 Short-term operating lease liabilities 958,992 — Total current liabilities 5,158,712 4,381,107 Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity — 64 Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and 86,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (162,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) (164,078,525) (164,078,525) (164,078,525) (162,078,525)	Deferred revenue		9,993		15,824	
Short-term operating lease liabilities 958,992 — Total current liabilities 5,158,712 4,381,107 Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity — 8 Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity — —	Short-term notes payable		343,330		398,595	
Total current liabilities 5,158,712 4,381,107 Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741	Short-term finance lease liabilities		576,322		399,345	
Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively —	Short-term operating lease liabilities		958,992		_	
Deferred rent — 162,919 Note payable 494,897 660,340 Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively —	Total current liabilities		5,158,712		4,381,107	
Warrant liability — 67 Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — <td>Deferred rent</td> <td></td> <td><i></i></td> <td></td> <td>162,919</td>	Deferred rent		<i></i>		162,919	
Long-term finance lease liabilities 379,825 437,189 Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively —	Note payable		494,897		660,340	
Long-term operating lease liabilities 1,071,677 — Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741	Warrant liability				67	
Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741	Long-term finance lease liabilities		379,825		437,189	
Total liabilities 7,105,111 5,641,622 Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741	Long-term operating lease liabilities		1,071,677		_	
Commitments Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively —					5,641,622	
Stockholders' equity Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741	Commitments		<u> </u>	_		
Common stock, \$0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741						
8,645,720 shares issued and outstanding at June 30, 2019 and 176,457 86,457 December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741						
December 31, 2018, respectively 176,457 86,457 Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741						
Preferred stock, \$0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741			176,457		86,457	
outstanding at June 30, 2019 and December 31, 2018, respectively — — Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741			,		,	
Additional paid-in capital 170,190,415 165,313,902 Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741			_		_	
Accumulated other comprehensive loss (15,217) (13,093) Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741			170,190,415		165,313,902	
Accumulated deficit (168,524,652) (162,078,525) Total stockholders' equity 1,827,003 3,308,741						
Total stockholders' equity 1,827,003 3,308,741	•					
	Total liabilities and stockholders' equity	\$	8,932,114	\$	8,950,363	

OpGen, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

	 Three Months 2019	Ended	June 30, 2018	Six Months F 2019	Ended J	une 30, 2018
Revenue						
Product sales	\$ 504,293	\$	632,525	\$ 1,024,470	\$	1,266,021
Laboratory services	5,250		1,100	5,250		9,790
Collaboration revenue	500,000		155,276	1,000,000		359,316
Total revenue	 1,009,543		788,901	2,029,720		1,635,127
Operating expenses	 					
Cost of products sold	198,493		303,663	419,195		646,495
Cost of services	251,981		179,402	396,463		347,955
Research and development	1,153,584		1,304,388	2,929,966		2,534,817
General and administrative	1,592,845		1,831,063	3,340,430		3,621,585
Sales and marketing	393,567		426,297	765,800		756,070
Impairment of right-of-use asset	_		_	520,759		
Total operating expenses	 3,590,470		4,044,813	8,372,613		7,906,922
Operating loss	 (2,580,927)		(3,255,912)	(6,342,893)		(6,271,795)
Other (expense) income					_	
Other income (expense)	15,166		5	(9,256)		5,303
Interest expense	(37,129)		(54,533)	(93,573)		(112,379)
Foreign currency transaction gains (losses)	9,879		(21,762)	(472)		(9,581)
Change in fair value of derivative financial instruments	_		(11)	67		8,155
Total other expense	 (12,084)		(76,301)	(103,234)		(108,502)
Loss before income taxes	 (2,593,011)		(3,332,213)	(6,446,127)		(6,380,297)
Provision for income taxes	_		_	_		_
Net loss	 (2,593,011)		(3,332,213)	(6,446,127)		(6,380,297)
Net loss available to common stockholders	\$ (2,593,011)	\$	(3,332,213)	\$ (6,446,127)	\$	(6,380,297)
Net loss per common share - basic and diluted	\$ (0.15)	\$	(0.57)	\$ (0.48)	\$	(1.29)
Weighted average shares outstanding - basic and diluted	 17,645,720		5,826,947	 13,518,648	-	4,950,517
Net loss	\$ (2,593,011)	\$	(3,332,213)	\$ (6,446,127)	\$	(6,380,297)
Other comprehensive (loss) gain - foreign currency translations	 (4,950)		18,113	 (2,124)		5,534
Comprehensive loss	\$ (2,597,961)	\$	(3,314,100)	\$ (6,448,251)	\$	(6,374,763)